颈动脉支架内再狭窄:再次支架与内膜剥脱术的荟萃分析
该荟萃分析纳入11项研究共1057例颈动脉支架内再狭窄患者,比较再次颈动脉支架术(rCAS,n=894)与颈动脉内膜剥脱术(CEA,n=163)的结局。两组在死亡/卒中无事件生存率(99% vs 98%)及其他次要终点上均无显著差异(P > .05)。rCAS与CEA治疗支架内再狭窄均安全,短期和中期卒中、死亡及手术相关并发症相似。
要点
- rCAS与CEA治疗颈动脉支架内再狭窄的死亡/卒中无事件率无显著差异(99% vs 98%)。
- 两组再狭窄、心肌梗死、颅神经损伤和颈部血肿的无事件率均无显著差异。
- CEA组症状性患者比例更高(42.1% vs 30.4%),从初次CAS到再干预时间更长。
核心结论
- rCAS与CEA治疗颈动脉支架内再狭窄的短期和中期卒中、死亡及手术相关并发症相似。
研究设计与样本
- 系统检索PubMed、Embase和Cochrane数据库,纳入报告rCAS或CEA治疗既往CAS后支架内再狭窄围手术期结局且病例数≥4的研究。
- 共纳入11项研究,1057例患者,其中rCAS组894例,CEA组163例。
主要发现
- CEA组症状性患者比例显著高于rCAS组(42.1% vs 30.4%,P < .01)。
- 从初次CAS到再干预的中位时间:rCAS组8.8个月(范围3-26个月),CEA组19.9个月(范围0-54个月)。
- rCAS组高血压、高胆固醇血症、冠心病及再干预前接受抗血小板治疗的患者比例更高。
- 主要终点死亡/卒中无事件率:rCAS组99% vs CEA组98%,P > .05。
- 次要终点无事件率(再狭窄100% vs 100%;心肌梗死100% vs 98%;颅神经损伤100% vs 98%;颈部血肿100% vs 100%)均无显著差异(P > .05)。
临床怎么用
- 对于颈动脉支架内再狭窄,rCAS和CEA均可作为安全选择,短期和中期结局相似。
- rCAS常用于治疗严重和/或症状性支架内再狭窄。
局限性
- 因数据不足或发生率低,仅再狭窄、心肌梗死、颅神经损伤和颈部血肿可进一步分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The development of in-stent restenosis (ISR) hinders the long-term patency of carotid artery stenting (CAS), yet no optimal treatment has been established. In the present study, we compared the outcomes of redo CAS (rCAS) and carotid endarterectomy (CEA) for ISR. METHODS: A systematic search using the terms "in-stent restenosis," "carotid endarterectomy," and "carotid artery stenting" was conducted in the PubMed, Embase, and Cochrane databases. Studies reporting perioperative stroke, death, and other important complications of rCAS or CEA for ISR after previous CAS with four or more patients were included. Pooled and sensitivity analyses were conducted to synthesize and compare estimates of the outcomes. RESULTS: A total of 11 studies with 1057 patients who had undergone rCAS (n = 894) or CEA (n = 163) met the inclusion criteria. The CEA group had a significantly greater proportion of symptomatic patients (rCAS vs CEA, 30.4% vs 42.1%; P < .01). The duration from primary CAS to reintervention was relatively longer in the CEA group (rCAS vs CEA, median, 8.8 months [range, 3-26 months] vs 19.9 months [range, 0-54 months]). In the rCAS group, a greater proportion of patients had hypertension, hypercholesterolemia, and coronary artery disease and had received antiplatelet therapy before reintervention. Because of insufficient data or a low incidence, the only complications feasible for further analysis were restenosis, myocardial infarction, cranial nerve injury, and neck hematoma. No significant differences were found in the primary end point of mortality/stroke event-free rate (rCAS vs CEA, 99% vs 98%; P > .05) or other secondary end points (event-free restenosis, 100% vs 100%; event-free myocardial infarction, 100% vs 98%; event-free cranial nerve injury, 100% vs 98%; event-free neck hematoma, 100% vs 100% for rCAS vs CEA; P > .05 for all). CONCLUSIONS: rCAS is commonly used to treat patients with severe and/or symptomatic ISR after primary CAS. Although the endovascular approach is less invasive, both rCAS and CEA can be performed safely with similar short- and midterm outcomes of stroke, death, and surgery-related complications.
引用
- Guo Z, Liu C, Huang K, et al. Meta-analysis of redo stenting versus endarterectomy for in-stent stenosis after carotid artery stenting. J Vasc Surg. 2020. PMID: 32861870. doi:10.1016/j.jvs.2020.07.102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。